In brief
Despite significant investments and job opportunities, Kalundborg grapples with community challenges, leading its residents to seek life elsewhere.
Kalundborg, a Danish coastal town with a population of 16,000, is experiencing what could be termed a modern economic phenomenon, primarily fueled by the production of Wegovy, a weight loss drug developed by Novo Nordisk. The company has funneled over $8.5 billion (£6.5bn) into the area—an investment nearly equal to Monaco's entire GDP. Yet, the town’s potential for growth remains unfulfilled due to various socio-economic hurdles. During peak hours, locals refer to the daily influx of workers at the factory and their subsequent departure as the "Novo Queue." Many of these workers commute from surrounding areas, leaving the town's population unchanged despite the substantial investment. This leads to the question: if £400,000 is spent per resident, why isn't Kalundborg flourishing? The reality is that Kalundborg faces substantial challenges, including struggling schools, low household incomes, and a concerning rate of childhood obesity. The state schools here fall below national performance averages, and there’s a lack of facilities in some neighborhoods, with only dilapidated parks available for children. Local policymakers, like regional councillor Helle Laursen Petersen, indicate that the area has difficulty attracting skilled teachers, resulting in diminished expectations from parents who feel their children may rely on jobs at Novo Nordisk rather than pursuing higher education. Opinions among local students vary; while some express interest in moving to larger cities for better opportunities, others remain hopeful about returning post-education, eager for local job prospects and the charm of Kalundborg's natural environment. Brian Sonder Anderson, local cinema owner and trader’s association leader, notes a bustling atmosphere at supermarkets and bakeries catering to factory workers during breaks. However, businesses that depend on long-term residents, such as clothing stores, often struggle to survive due to low demand. Many locals are unable to afford housing in Copenhagen, causing reliance on jobs at the Novo Nordisk facility and contributing to regional economic challenges. The town also holds the unfortunate distinction of having a significantly high rate of childhood obesity, emphasizing a need for improved health and lifestyle initiatives. As Novo Nordisk flourishes—boasting over $33 billion in revenue—investment in Kalundborg aims to create approximately 1,250 new jobs to ramp up production capacities. While the pharmaceutical industry plays a vital role in Denmark’s robust economic growth, experts warn of potential over-reliance on this sector.Kalundborg's mayor, Martin Damm, remains optimistic, citing over 1,000 new jobs being created annually and the town’s unique attractiveness, bucking the trend of migration toward major cities. New university programs have drawn international students, such as Miguel from Madrid, who appreciates the multicultural community developing in the town. A highway project is underway to alleviate heavy traffic, but the real challenge lies in making Kalundborg a desirable place to live. Students voice a mix of hope and skepticism about the town’s future, envisioning a growth trajectory that could lead them to eventually stay or return to Kalundborg.
